BC Week In Review | Sep 12, 2016
Clinical News

TXA709 regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to TXA709 from Taxis to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by Staphylococcus aureus, including methicillin-resistant strains. The company expects the S. aureus...
BC Week In Review | Sep 28, 2015
Clinical News

Taxis Pharmaceuticals preclinical data

Taxis said oral TXA709 plus cefdinir showed synergistic activity against all MRSA strains tested in a mouse model of peritonitis systemic infection. Additionally, the combination significantly reduced detectable frequency of resistance (FOR), a measure of...
BC Innovations | Jun 4, 2015
Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
Items per page:
1 - 3 of 3